Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.58 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CDK4 | P11802 | 3/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CCND1 | P24385 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91469 | 0.88 | CTSK (0.49) | IKBKBCDK1CDK4CCNB1CCNA2 | |
| SCHEMBL91478 | 0.85 | CTSK (0.58) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL91484 | 0.83 | CTSK (0.60) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL13693348 | 0.82 | BRD4 (0.52) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL13524818 | 0.82 | BRD4 (0.52) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL19477097 | 0.81 | HRH3 (0.56) | IKBKBCDK1CDK4CCNB1CCNA2 | |
| SCHEMBL24065221 | 0.81 | CDK1 (0.54) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL18677322 | 0.81 | CDK1 (0.54) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL15830033 | 0.81 | MAPK1 (0.62) | MKNK1MAPK8MAPK1HRH4MKNK2 | |
| SCHEMBL8303185 | 0.81 | HRH3 (0.59) | IKBKBCDK1CDK4CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164612-A9 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023164612-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| US-7998969-B2 | enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases | ROCHE PALO ALTO LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2005037828-A1 | NOVEL INHIBITORS OF DPP-IV, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | NQO2, SAMHD1, POLR2A | IKBKB 1774/4885CDK1 133/4885CDK4 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.